Furanosyl Nucleoside Analogues Embodying Triazole or Theobromine Units as Potential Lead Molecules for Alzheimer's Disease
Log in with Open Athens, Shibboleth, or your institutional credentials.
If you have previously obtained access with your personal account, Please log in.
If you previously purchased this article, Log in to Readcube.
You previously purchased this article on READCUBE_PURCHASE_DATE. Click on an option below to access.
Logged in as READCUBE_USER. Log out of ReadCube.
Abstract
The synthesis of novel types of furanosyl nucleoside analogues, namely N‐(benzyltriazolyl)methyl glucuronamide derivatives, N‐dodecyl glucuronamide‐based phenyltriazole nucleosides, and theobromine xylosyl 5′‐isonucleosides, as potential cholinesterase inhibitors is described herein. O‐Substituted and partially O‐substituted N‐propargyl glucuronamides, accessed from glucofuranurono‐6,3‐lactone, were engaged in CuI‐catalyzed cycloaddition with benzyl azide, whereas their N‐dodecyl uronamide counterparts were converted in three steps into glycosyl azides, which were subjected to cycloaddition with phenylacetylene. A xylofuranose derivative having a free 5‐OH group was coupled with theobromine by Mitsunobu reaction and the obtained isonucleoside was functionalized at C‐1′ with a sulfonamide moiety, leading to a prospective nucleotide mimetic. Five compounds displayed selective inhibition of acetylcholinesterase in the micromolar concentration range, with an α‐glycosyl triazole (Ki = 3.53 µm) and its 1‐azido‐uronamide precursor (Ki = 1.73 µm) being the most active. Docking studies were performed to give insights into the different inhibitory behavior within glycosyl azide anomers. Two of the best inhibitors showed low toxicity in both a neural cell line and human fibroblasts, rendering them promising lead compounds and supporting further investigations.
Number of times cited according to CrossRef: 1
- Nuno M. Xavier, Rita Goncalves-Pereira, Radek Jorda, Denisa Hendrychová and M. Conceição Oliveira, Novel dodecyl-containing azido and glucuronamide-based nucleosides exhibiting anticancer potential, Pure and Applied Chemistry, 10.1515/pac-2019-0106, 0, 0, (2019).
